Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase II Clinical Trial to Explore the Safety and Efficacy of Simmitinib Plus Irinotecan Liposome in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT06512428 is registered in ClinicalTrials.gov with Shanghai Runshi Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT06512428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06512428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase II Clinical Trial to Explore the Safety and Efficacy of Simmitinib Plus Irinotecan Liposome in Patients With Advanced Esophageal Squamous Cell Carcinoma
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
March 15, 2024
Completion date
January 30, 2026
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal squamous cell carcinoma